Source: Eur Respir Rev 2009; 18: 195-197
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Berry M., Kon O. M.. Multidrug- and extensively drug-resistant tuberculosis: an emerging threat. Eur Respir Rev 2009; 18: 195-197

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016 Extensively drug-resistant tuberculosis: back to the future Source: Eur Respir J 2010; 36: 475-477 Year: 2010 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city Source: Eur Respir J 2013; 41: 901-908 Year: 2013 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008 Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 872-873 Year: 2013 A case of resistance beyond extensively drug-resistant tuberculosis in Japan Source: Eur Respir J 2013; 42: 870-872 Year: 2013 Risk factors for multidrug-resistant and extensively drug-resistant tuberculosis in Estonia Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012